NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

# Diagnostics Advisory Committee (DAC)

**Minutes of the Meeting held on Thursday 3 September 2020**

**via Zoom**

**PRESENT:**

**Standing Committee members:**

Dr Mark Kroese (Chair)

Professor Keith Abrams

Ms Liz Adair

Mr John Bagshaw

Professor John Cairns

Professor Enitan Carrol

Dr Jim Gray

Professor Steve Halligan

Professor Neil Hawkins

Mr Ross Maconachie

Mr Patrick McGinley

Mrs Alexandria Moseley

Dr Shelley Rahman Haley

Dr Alistair Reid

Dr Brian Shine

Professor Matt Stevenson

**Standing Committee apologies:**

Ms Rebecca Allcock

Dr Owen Driskell

Dr Michael Messenger

**NICE staff in attendance:**

Rebecca Albrow, Associate Director, DAP

Frances Nixon, HTA Adviser, DAP

Peter O’Neill, HTA Adviser, DAP

Simon Webster, (Technical lead), HTA Analyst, DAP

Donna Barnes, Project Manager, DAP

Alex Sexton, Administrator, DAP

Observing:

Helen Crosbie, Public Involvement Adviser

Ann Greenwood, Editor

Suvi Harmala, HTA Analyst, DAP

Cheryl Hookway, Health Technology Adoption Manager

Ian Mather, Business Analyst – Resource Impact

Sophie McHugh, Administrator, CHTE

Rosalee Mason, Coordinator, Corporate Office

Tosin Oladapo, HTA Analyst, DAP

1. **Introduction to the meeting**

The Chair welcomed committee members, observers, and members of the public.

Apologies were noted.

1. **Code of conduct for members of the public attending the meeting**

The Chair explained the code of conduct to the members of the public attending this meeting.

1. **Any other business**

The Chair recorded the committee’s thanks to Professor Enitan Carrol and Professor Steve Halligan for all their work and valuable contributions during their time as members of the Diagnostics Advisory Committee.

1. **Minutes from the last Committee meeting**

The Committee agreed the minutes from the 6 August 2020 meeting.

1. **Equality and Diversity**

The Chair reminded the Committee to raise any potential equality issues related to the topic under discussion.

QAngio XA 3D/QFR and CAAS vFFR imaging software for assessing coronary stenosis during invasive coronary angiography

External Assessment Group representatives: University of York

 Mark Simmonds - Centre for Reviews and Dissemination (CRD)

 Claire Rothery - Centre for Health Economics (CHE)

 Ana Duarte – Centre for Health Economics (CHE)

**Specialist Committee members:**

Dr Gerald Clesham, Consultant Cardiologist

Diane Davis, Lay specialist

Dr Timothy Fairbairn, Consultant Cardiologist

Dr Ian Purcell, Consultant General and Interventional Cardiologist

**PART 1 AND PART 2 (open and closed parts of the meeting)**

Part 1 – Open session

The Chair welcomed representatives from Pie Medical Imaging and Medis Medical Imaging Systems Bv.

There were 8 public attendees.

The Chair asked Committee members to declare any relevant interests.

The following standing committee members had notified these interests in advance of the meeting:

Professor Keith Abrams had declared a financial interest as he is a Partner & Director, Visible Analytics Limited, an HTA Consultancy company, but has not been involved in any projects which involve a diagnostic technology. He had also declared a non-financial personal and professional interest as he has received funding to support a MRC Industrial PhD Studentship from Swiss Precision Diagnostics/Clearblue for a project on prediction of early miscarriage. It was agreed that these interests did not preclude him from participating in the meeting.

Patrick McGinley had declared non-financial professional and personal interests as since September 2019 he has been a member of the Strategic Council for the All-Party Parliamentary Group (APPG) on Obesity and also a co-opted member the Association for Study of Obesity (ASO) Trustees. He had also declared a financial interest as since January 2020 he has been a Faculty member of MTech Access, for which he receives an honorarium for advice on NHS Finance. The work has not involved any of the companies and/or the tests included in the assessment. It was agreed that these interests did not preclude him from participating in the meeting.

The following specialist committee members had notified these interests in advance of the meeting:

Dr Gerald Clesham had declared a financial interest as he has an unrestricted grant from Abbott Ltd to support MD research project. It was agreed that this interest did not preclude him from participating in the meeting.

Dr Timothy Fairburn had declared an indirect interest as he is on the Speakers Bureau for Heartflow. It was agreed that this interest did not preclude him from participating in the meeting.

Dr Ian Purcell had declared that since May 2016 he has been the Principal Investigator (PI) for the ADVANCE study in CT FFR sponsored by HeartFlow. He had also declared that in March 2017 he had attended a one-week training course in CT coronary angiography in Vancouver funded by HeartFlow. The training was arranged to support his role as PI for two research studies (PLATFORM and ADVANCE) sponsored by HeartFlow. He had further declared that he had presented data on CT FFR and invasive FFR at a medical conference (OxCore) sponsored by Abbott Vascular in October 2019 and received a speaker honorarium. It was agreed that these interests did not preclude him from participating in the meeting.

The Committee proceeded to discuss the clinical effectiveness and cost effectiveness of QAngio XA 3D/QFR and CAAS vFFR imaging software for assessing coronary stenosis during invasive coronary angiography.

The Committee was asked if there were any specific equality issues to consider in relation to this assessment.

The Chair asked the representatives of the manufacturers whether they wished to comment on any matters of factual accuracy.

The Chair explained that “representatives of the press and other members of the public be excluded from the remainder of this meeting having regard to the confidential nature of the business to be transacted, publicity on which would be prejudicial to the public interest" (Section 1(2) Public Bodies (Admission to Meetings) Act 1960)” and all public attendees left the meeting.

The Chair thanked the manufacturer representatives, the EAG and public observers for their attendance at the meeting.

End of Part 1

Part 2 – closed session

Agreement on the content of the Diagnostics Consultation Document (DCD) was discussed by the committee.

End of Part 2

Date of next meeting (next topic): Wednesday 7 October 2020.